Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling

Clinical Cancer Research

Volumn 13, Issue 22, 2007, Pages 6753-6760

  Li, Ling ^a,a   Pan, Qiangrong ^a   Han, Weidong ^a   Liu, Zhen ^a   Hu, Xun ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P INHIBITOR; MALONALDEHYDE; MATRIX METALLOPROTEINASE; SCHISANDRIN B; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME RELEASE; HEART FUNCTION; HEART INJURY; HEART MUSCLE CELL; MALE; MORTALITY; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CYCLOOCTANES; DOXORUBICIN; GLUTATHIONE; HEART DISEASES; LIGNANS; MICE; MICE, INBRED ICR; OXIDATION-REDUCTION; POLYCYCLIC COMPOUNDS;

EID: 36749096845     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1579     Document Type: Article

References (41)

1. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
2. Fogli S, Nieri P, Breschi MC. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J 2004;18:664-75.
3. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005;131:561-78.
4. Peng X, Chen B, Lim CC, Sawyer DB. The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. Mol Interv 2005;5:163-71.
5. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
6. Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 2006;86:849-99.
7. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. JPathol 2005;205:275-92.
8. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934-49.
9. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13:2688-99.
10. Feldman AM, Lorell BH, Reis SE. Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 2000;102:272-4.
11. Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 2001;108:585-90.
12. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumabc linical trials experience. J Clin Oncol 2002;20:1215-21.
13. Qiangrong P, Wang T, Lu Q, Hu X. Schisandrin B - a novel inhibitor of P-glycoprotein. Biochem Biophys Res Commun 2005;335:406-11.
14. Pan Q, Lu Q, Zhang K, Hu X. Dibenzocyclooctadiene lignans: a class of novel inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 2006;58:99-106.
15. Sun M, Xu X, Lu Q, Pan Q, Hu X. Schisandrin B: a dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1. Cancer Lett 2007;246:300-7.
16. Li L, Pan Q, Sun M, Lu Q, Hu X. Dibenzocyclooctadiene lignans: a class of novel inhibitors of multidrug resistance-associated protein 1. Life Sci 2007;80:741-8.
17. Wan CK, Zhu GY, Shen XL, Chattopadhyay A, Dey S, Fong WF. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells. Biochem Pharmacol 2006;72:824-37.
18. Fong WF, Wan CK, Zhu GY, et al. Schisandrol A from Schisandra chinensis reverses P-glycoprotein-mediated multidrug resistance by affecting Pgp-substrate complexes. Planta Med 2007;73:212-20.
19. Li L, Lu Q, Shen Y, Hu X. Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells. Biochem Pharmacol 2006;71:584-95.
20. Ip SP, Poon MK, Wu SS, et al. Effect of schisandrin B on hepatic glutathione antioxidant system in mice: protection against carbon tetrachloride toxicity. Planta Med 1995;61:398-401.
21. Chiu PY, Ko KM. Schisandrin B protects myocardial ischemia-reperfusion injury partly by inducing Hsp25 and Hsp70 expression in rats. Mol Cell Biochem 2004;266:139-44.
22. Ko KM, Lam BY. Schisandrin B protects against tert-butylhydroperoxide induced cerebral toxicity by enhancing glutathione antioxidant status in mouse brain. Mol Cell Biochem 2002;238:181-6.
23. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. JClin Invest 1980;65:128-35.
24. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. Probucol protects against Adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995;91:10-5.
25. Pacher P, Liaudet L, Bai P, et al. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 2003;107:896-904.
26. Koyama H, Iwata H, Kuwabara Y, Iwase H, Kobayashi S, Fujii Y. Gelatinolytic activity of matrix metalloproteinase-2 and -9 in oesophageal carcinoma; a study using in situ zymography. Eur J Cancer 2000;36:2164-70.
27. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978;52:302-10.
28. Carlberg I, Mannervik B. Glutathione reductase. Methods Enzymol 1985;113:484-90.
29. Flohe L, Gunzler WA. Assays of glutathione peroxidase. Methods Enzymol 1984;105:114-21.
30. Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 1974;249:7130-9.
31. Tietze F. Enzymic method for quantitative determination of nanogramamounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 1969;27:502-22.
32. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988;34:497-500.
33. Goth L. A simple method for determination of serum catalase activity and revision of reference range. Clin Chim Acta 1991;196:143-51.
34. Kang YJ, Chen Y, Yu A, Voss-McCowan M, Epstein PN. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J Clin Invest 1997;100:1501-6.
35. Pacher P, Liaudet L, Bai P, et al. Activation of poly(-ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 2002;300:862-7.
36. Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways. J Biol Chem 2004;279:25535-43.
37. Wang S, Kotamraju S, Konorev E, Kalivendi S, Joseph J, Kalyanaraman B. Activation of nuclear factor-κB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem J 2002;367:729-40.
38. Nobori K, Ito H, Tamamori-Adachi M, et al. ATF3 inhibits doxorubicin-induced apoptosis in cardiac myocytes: a novel cardioprotective role of ATF3. J Mol Cell Cardiol 2002;34:1387-97.
39. Kang PM, Yue P, Izumo S. New insights into the role of apoptosis in cardiovascular disease. Circ J 2002;66:1-9.
40. Siveski-Iliskovic N, Kaul N, Singal PK. Probucol promotes endogenous antioxidants and provides protection against Adriamycin-induced cardiomyopathy in rats. Circulation 1994;89:2829-35.
41. Li T, Singal PK. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation 2000;102:2105-10.